SCHEMBL9892663

SCHEMBL9892663

O=C(O)Cc1ccc(C(F)(F)F)cc1-c1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 1/20 0.49
TRPV1 Q8NER1 1/20 0.47
PTGDR2 Q9Y5Y4 5/20 0.47
RXRA P19793 4/20 0.46
RXRB P28702 3/20 0.46
RXRG P48443 3/20 0.46
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KCNA5 P22460 1/20 0.44
KCNH2 Q12809 1/20 0.44
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44
PSENEN Q9NZ42 1/20 0.44
TBXA2R P21731 1/20 0.42
PTGDR Q13258 1/20 0.42
CTSA P10619 1/20 0.42
CHRM3 P20309 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9892655 0.89 PTGDR2 (0.47) GCGRPTGDR2RXRARXRBRXRG
SCHEMBL2395233 0.88 ICMT (0.53) GCGRTRPV1PTGDR2KCNA5KCNH2
SCHEMBL9892681 0.87 PTGDR2 (0.59) PTGDR2RXRARXRBRXRGPSEN1
SCHEMBL9890666 0.86 PTGDR2 (0.50) PTGDR2RXRAKDM4ESMN1; SMN2TBXA2R
SCHEMBL9890680 0.81 SRC (0.47) PTGDR2KDM4ESMN1; SMN2TBXA2RPTGDR
SCHEMBL2531179 0.80 TAAR1 (0.46) GCGRTRPV1PTGDR2KCNA5KCNH2
SCHEMBL9105295 0.80 PTGER1 (0.57) PTGDR2KDM4ESMN1; SMN2TBXA2RPTGDR
SCHEMBL9890640 0.79 PTGER1 (0.53) PTGDR2RXRARXRBRXRG
SCHEMBL9890679 0.79 KDM4E (0.49) PTGDR2KDM4ESMN1; SMN2TBXA2RPTGDR
SCHEMBL1690286 0.78 PTGDR2 (0.79) PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 GCGR 1918/4885TRPV1 1190/4885PTGDR2 1062/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 GCGR 1918/4885TRPV1 1190/4885PTGDR2 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.